Assessment of adherence to triple antiretroviral treatment including indinavir: Role of the determination of plasma levels of indinavir

被引:28
作者
Alcoba, M
Cuevas, TJ
Perez-Simon, MR
Mostaza, TL
Ortega, L
de Urbina, JO
Carro, JA
Raya, T
Abad, M
Martin, V
机构
[1] Univ Leon, Dept Physiol, E-24071 Leon, Spain
[2] Univ Leon, Leon Hosp, E-24071 Leon, Spain
[3] El Bierzo Hosp, Ponferrada, Spain
关键词
adherence; indinavir; questionnaires; pharmacy; plasma levels; HAART;
D O I
10.1097/00126334-200306010-00022
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To assess the contribution of the determination of concentrations of indinavir (IND) in plasma to the assessment of self-reported adherence and keeping of appointments to withdraw drugs from the hospital pharmacy. Patients and Methods: Adherence was assessed using three criteria: questionnaires, punctuality at appointments to withdraw drugs, and plasma concentrations of IND. Blood samples were obtained from 106 HIV-infected patients who had been receiving IND in combination with two nucleoside reverse transcriptase inhibitors for longer than 6 months. Logistic regression analysis was carried out, and receiver operating characteristic curves were drawn. Results: The kappa index showed a low concordance for the three measures. When pharmacy appointments and self-report are used together, the nondetection of drug levels is more reliably predicted (AUC = 0.75). With the viral load as the gold standard, plasma levels contribute nothing to the information given by the other two measures combined (AUC = 0.63, AUC = 0.64). Conclusion: Measurement of adherence to highly active antiretroviral therapy is complex. Because there is no gold standard for it, we demonstrated that each of three common adherence measures has shortcomings that can be minimized in a combined measurement system. Indinavir plasma levels appear to provide no additional information, so further studies are undoubtedly necessary.
引用
收藏
页码:253 / 258
页数:6
相关论文
共 22 条
  • [1] [Anonymous], 1994, EPI INFO VERSION 6 W
  • [2] [Anonymous], 2000, EPI INFO 2000 DATABA
  • [3] Chesney MA, 1999, AIDS, V13, pS271
  • [4] Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy
    Descamps, D
    Flandre, P
    Calvez, V
    Peytavin, G
    Meiffredy, V
    Collin, G
    Delaugerre, C
    Robert-Delmas, S
    Bazin, B
    Aboulker, JP
    Pialoux, G
    Raffi, F
    Brun-Vézinet, F
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (02): : 205 - 211
  • [5] Value of patient self-report and plasma human immunodeficiency virus protease inhibitor level as markers of adherence to antiretroviral therapy: Relationship to virologic response
    Duong, M
    Piroth, L
    Peytavin, G
    Forte, F
    Kohli, E
    Grappin, M
    Buisson, M
    Chavanet, P
    Portier, H
    [J]. CLINICAL INFECTIOUS DISEASES, 2001, 33 (03) : 386 - 392
  • [6] Sociodemographic and psychological variables influencing adherence to antiretroviral therapy
    Gordillo, V
    del Amo, J
    Soriano, V
    González-Lahoz, J
    [J]. AIDS, 1999, 13 (13) : 1763 - 1769
  • [7] Günthard HF, 1998, J VIROL, V72, P2422
  • [8] Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers
    Hsu, A
    Granneman, GR
    Cao, GL
    Carothers, L
    Japour, A
    El-Shourbagy, T
    Dennis, S
    Berg, J
    Erdman, K
    Leonard, JM
    Sun, EG
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (11) : 2784 - 2791
  • [9] Hugen PWH, 2002, J ACQ IMMUN DEF SYND, V30, P324, DOI [10.1097/01.QAI.0000014768.35851.DB, 10.1097/00126334-200207010-00009]
  • [10] John L, 2001, ANN PHARMACOTHER, V35, P745